在上皮性卵巢癌 (EOC) 患者中，针对 PD-1/PD-L1 的免疫检查点抑制剂 (ICIs) 单一疗法的临床疗效有限。为了提高对这些免疫治疗药物的反应率并扩大其使用适应症，需要涉及联合治疗的新方法。免疫调节剂 CD73 是一个潜在的靶点，因为它通过在肿瘤微环境中产生免疫抑制性细胞外腺苷来促进肿瘤逃逸。在此，我们介绍 NSGO-OV-UMB1/ENGOT-OV-30 试验的结果，该试验评估抗 CD73 抗体 oleclumab 与抗 PD-L1 检查点抑制剂 durvalumab 联合治疗复发性 EOC 患者的活性。 II 开放标签非随机研究，CD73 阳性复发性 EOC 患者静脉注射 oleclumab（3000 mg，Q2W）和 durvalumab（1500 mg，Q4W）。主要终点是 16 周时的疾病控制率 (DCR)。通过档案肿瘤的免疫组织化学评估 PD-L1 和 CD8 的表达。该试验包括 25 名患者，中位年龄为 66 岁（47-77 岁）。 22 名患者可进行治疗活动分析评估。 DCR 为 27%，中位无进展生存期为 2.7 个月（95% CI：2.2-4.2），中位总生存期为 8.4 个月（95% CI：5.0-13.4）。在部分重叠的 74% 肿瘤样本组中观察到 CD8 细胞浸润和肿瘤细胞上的 PD-L1 表达。 CD8 阳性和 PD-L1 阳性均与更好的 DCR 没有显着相关性。 oleclumab 和 durvalumab 联合治疗是安全的，并且在复发性 EOC 患者中显示出有限的抗肿瘤活性。版权所有 © 2024。由 Elsevier Inc. 出版。

In patients with epithelial ovarian cancer (EOC), the clinical efficacy of monotherapy with immune checkpoint inhibitors (ICIs) against PD-1/PD-L1 is modest. To enhance response rates to these immunotherapeutic agents and broaden the indications for their use, new approaches involving combinational therapy are needed. The immune regulator CD73 is a potential target, as it promotes tumor escape by producing immunosuppressive extracellular adenosine in the tumor microenvironment. Here, we present the results from the NSGO-OV-UMB1/ENGOT-OV-30 trial evaluating the activity of combining the anti-CD73 antibody oleclumab with the anti-PD-L1 checkpoint inhibitor durvalumab in patients with recurrent EOC.In this phase II open-label non-randomized study, patients with CD73-positive relapsed EOC were intravenously administered oleclumab (3000 mg, Q2W) and durvalumab (1500 mg, Q4W). The primary endpoint was disease control rate (DCR) at 16 weeks. The expression of PD-L1 and CD8 was assessed by immunohistochemistry of archival tumors.This trial included 25 patients with a median age of 66 years (47-77 years). Twenty-two patients were evaluable for treatment activity analysis. The DCR was 27%, the median progression-free survival was 2.7 months (95% CI: 2.2-4.2) and the median overall survival was 8.4 months (95% CI: 5.0-13.4). Infiltration of CD8+ cells and PD-L1 expression on tumor cells were observed in partially overlapping sets of 74% of the tumor samples. Neither CD8- nor PD-L1-positivity were significantly associated with better DCR.Combined treatment with oleclumab and durvalumab was safe and demonstrated limited anti-tumor activity in patients with recurrent EOC.Copyright © 2024. Published by Elsevier Inc.